Quest Diagnostics (DGX) and the Case for a $260 Price Target
Key Takeaways
- The selected price target is $260 per share, roughly 10% above Quest Diagnostics' recent close near $236.
- The strongest bullish factors include solid organic revenue growth, expansion in high-value advanced diagnostics, and an active acquisition strategy.
- The biggest risks are potential reimbursement pressure, a richer valuation, and execution risk tied to M&A integration.
- Key levels include the 52-week high near $248.84 and the $250 psychological zone as near-term resistance, with prior support in the $225–$232 area.
- The key takeaway: $260 is a demanding but not unrealistic objective that likely hinges on continued earnings momentum.
Why the $260 Level Stands Out
Quest Diagnostics Incorporated (DGX), one of the largest independent providers of diagnostic testing and information services in the United States, has attracted attention as investors look for a credible price target above its recent trading range. The $260 level stands out because it sits near the top of the current Wall Street forecast range. Multiple firms, including Morgan Stanley and Argus Research, have published price targets at or around $260, making it a meaningful psychological and analytical milestone rather than an arbitrary round number.
Current Market Position
Quest Diagnostics trades on the New York Stock Exchange and recently closed near $236, after a strong run that lifted the shares well off their 52-week low of about $171. The stock's 52-week high sits near $248.84, meaning the $260 target represents a new record level that has not yet been reached. With a market capitalization of roughly $26 billion, a trailing price-to-earnings (P/E) ratio near 25, and a forward P/E of about 20, the shares reflect investor confidence in the company's steady, defensive growth profile. From what I see, the valuation already prices in a fair amount of stability.
Drivers That Could Support Further Gains
Quest Diagnostics has built momentum through a combination of core-volume growth and expansion into faster-growing testing categories. Its physician and hospital channels have delivered consistent organic gains, while partnerships such as Collaborative Lab Solutions continue to deepen hospital relationships. The company has also pursued an aggressive acquisition strategy, including the LifeLabs deal that expanded its Canadian footprint and the purchase of select clinical testing assets tied to Fresenius Medical Care's Spectra Laboratories.
Advanced diagnostics represent perhaps the most compelling long-term catalyst. Quest's AD-Detect blood test for Alzheimer's disease has posted sustained double-digit growth, while its Haystack minimal residual disease (MRD) testing platform is building a presence in oncology and received FDA breakthrough device designation. Success in these higher-margin areas could support both earnings growth and valuation expansion, key ingredients for a move toward $260. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Analyst Consensus and Recent Targets
The analyst community remains broadly constructive. According to S&P Global data, 17 analysts tracked give Quest Diagnostics a consensus "Buy" rating with an average one-year price target near $248. The spread is wide: the lowest target is around $204, while the highest reaches approximately $265. Recent activity has leaned bullish, with several firms raising targets into the $245–$260 range following strong quarterly results and raised guidance. This places the $260 target modestly above consensus but squarely within the range of the Street's most optimistic scenarios.
Technical Levels Worth Monitoring
From a technical analysis standpoint, the $248.84 52-week high is the first meaningful hurdle. A decisive breakout above that level would open the path toward the $250 round-number resistance and, ultimately, $260. On the downside, the $225–$232 zone has acted as prior support and would be an important area to hold during any pullback. The stock's low beta of roughly 0.55 underscores its reputation as a relatively stable, defensive holding within the healthcare services sector. One thing that stands out here is how the pattern recognition tools can help confirm these levels in real time.
Risks That Could Limit Upside
Several obstacles could prevent a run to $260. Reimbursement policy remains a persistent overhang, as changes to laboratory fee schedules or shifts in payer behavior could pressure test volumes and margins. Competition from rivals such as Labcorp (LH) keeps pricing disciplined. The shares also carry a valuation premium after their recent advance, leaving less room for error if organic growth slows or acquisition integrations underperform expectations. A broader rotation away from defensive healthcare names could also limit upside even if fundamentals stay intact.
Integrating AI Signals Into the Analysis
Traders monitoring Quest Diagnostics may also find value in automated tools that track shifting market conditions. I’ve found that reviewing AI-generated signals alongside traditional research helps highlight when momentum is building or fading, especially around key technical zones like the 52-week high.
Final Assessment
Reaching $260 would require Quest Diagnostics to clear its 52-week high and sustain the earnings momentum that has driven its recent rally. The strongest supporting factors are durable organic growth, an expanding advanced-diagnostics pipeline, and a steady flow of value-creating acquisitions. The primary risks are reimbursement uncertainty, a fuller valuation, and execution challenges tied to M&A. For investors, the key variables to monitor are quarterly volume trends, progress on the Haystack MRD and AD-Detect platforms, and any regulatory or payer policy changes. On balance, $260 appears ambitious but within reach if the company's current growth trajectory continues. I'm watching this closely for any signs of acceleration or stall.
Exploring Tickeron’s AI Daily Buy/Sell Signals
In my own research process, I often turn to Tickeron’s AI Daily Buy/Sell Signals to get an additional layer of insight. The tool scans thousands of stocks and ETFs in real time, generating Buy, Sell, or Hold signals based on technical behavior and AI-driven analysis. It has helped me spot emerging opportunities and monitor positions more efficiently than manual chart reviews alone, serving as a useful complement when evaluating names like DGX.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DGX in upward trend: price expected to rise as it breaks its lower Bollinger Band on September 10, 2026
DGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 19 of 29 cases where DGX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 66%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +5.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where DGX advanced for three days, in 197 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 186 of 295 cases where DGX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DGX as a result. In 35 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 41%.
The Moving Average Convergence Divergence Histogram (MACD) for DGX turned negative on September 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 20 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 47%.
DGX moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DGX crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 33%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 44%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.489) is normal, around the industry mean (72.578). P/E Ratio (25.225) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (1.546) is also within normal values, averaging (3.473). DGX's Dividend Yield (0.014) is considerably higher than the industry average of (0.001). P/S Ratio (2.404) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 20 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. DGX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of diagnostic testing and information services
Industry MedicalSpecialties
Advertisement